Evidence map›Paper›PMID 33597921›Full record

ArticleFrontiers in endocrinology2020

Initial Ablation Ratio Predicts Volume Reduction and Retreatment After 5 Years From Radiofrequency Ablation of Benign Thyroid Nodules.

Stella Bernardi, Marco Cavallaro, Giacomo Colombin, Fabiola Giudici, Giulia Zuolo, Adrian Zdjelar, Chiara Dobrinja, Nicolò De Manzini, Fabrizio Zanconati, Maria Assunta Cova and 2 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Stella BernardiDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
Marco CavallaroUnit of Radiology, Ospedale Maggiore, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy.
Giacomo ColombinDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
Fabiola GiudiciDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
Giulia ZuoloDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
Adrian ZdjelarDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
Chiara DobrinjaDepartment of General Surgery, Ospedale di Cattinara, Azienda Sanitaria Giuliano-Isontina, Trieste, Trieste, Italy.
Nicolò De ManziniDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
Fabrizio ZanconatiDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
Maria Assunta CovaDepartment of Medical Sciences, University of Trieste, Trieste, Italy.
Fulvio StaculUnit of Radiology, Ospedale Maggiore, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy.
Bruno FabrisDepartment of Medical Sciences, University of Trieste, Trieste, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Radiofrequency ablation (RFA) has gained ground as an effective and well-tolerated technique to treat benign thyroid nodules. Most of the available studies have described the short-term outcomes of RFA, whereas there is a limited number of studies evaluating long-term issues, such as regrowth and the likelihood of retreatments. In addition, risk markers of regrowth and retreatment remain to be defined. The initial ablation ratio (IAR) is an index that measures the amount of ablation after RFA, which has been associated with technique efficacy (i.e. volume reduction >50% after 1 year from the procedure). This study aimed at evaluating i) IAR reproducibility and ii) IAR predictive value for RFA 5-year outcomes. Materials and Methods: This is a retrospective single center study on patients with benign thyroid nodules treated with RFA and followed for 5 years after initial treatment. IAR interobserver reproducibility was evaluated with Bland-Altman method and Lin's concordance correlation coefficient (ρc). IAR predictive value for RFA 5-year outcomes was evaluated with linear and logistic regression models, as well as with Cox models, while receiver operating characteristic (ROC) analyses were used for cut-offs. Results: We selected 78 patients with 82 benign thyroid nodules. The procedure significantly reduced nodule volume and this reduction was generally maintained over time. Technique efficacy was achieved in 92% of patients, while 23% of nodules regrew and 12% of nodules were retreated. Median IAR was 83%. Lin's concordance and Pearson's correlation coefficients suggested a good interobserver reproducibility of this index, consistent with the limits of agreement of the Bland-Altman plot. IAR was significantly associated with technique efficacy, 1- and 5-year volume reduction ratio, and with the likelihood of a retreatment, but not with nodule regrowth. ROC analyses showed that IAR cut-off was 49% for technique efficacy and 73% for retreatment. Conclusions: Our results show for the first time that IAR is reproducible and that it predicts the volume reduction and the likelihood of a retreatment after 5 years from RFA.

Indexed as

AdolescentAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedObserver VariationPrognosisRadiofrequency AblationRetreatmentRetrospective StudiesThyroid NoduleTime Factors5 yearsefficacyinitial ablation ratio (IAR)radiofrequency ablation (RFA)regrowthretreatmentthyroid

Identifiers

PMID33597921
PMCPMC7883676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.